Clinical trial · Observational

A Multicenter, Real-world Study of Adebrelimab in the Treatment of Extensive Stage Small Cell Lung Cancer

A Multicenter, Real-world Study of Adebrelimab in the Treatment of Extensive Stage

NCT06267170CI-TRIAL-00074095SCLCunknownClinicalTrials.gov clinicaltrialsPublishedExplore in graph →

Summary

Brief summary (as posted)

This study collected data on patients with extensive stage small cell lung cancer treated with Adebrelimab to investigate its safety and efficacy

Conditions

Conditions (1)

Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.

Condition (as posted)	Mapped entity	Match	Confidence
SCLC,Extensive Stage	Lung Small Cell Carcinoma	CURATED_BROADER	0.78

Interventions

Interventions (1)

Intervention	Type	Mapped drug	Match
Adebrelimab	Drug	Adebrelimab	ALIAS

Design

Arms and outcomes

Arms (0)

[]

Primary outcomes (1)

measure
Safety (Occurrence of ≥ Grade 3 AE)
timeFrame
End of each cycle (each cycle is 28 days)
description
The incidence of grade 3 or higher adverse events

Secondary outcomes (4)

measure
PFS
timeFrame
End of every two cycles (each cycle is 28 days)
description
Progression free survival
measure
ORR
timeFrame
End of every two cycles (each cycle is 28 days)
description
Objective response rate
measure

Eligibility

Eligibility (as posted)

Sex: All
Minimum age: 18 Years

Show eligibility criteria text

Inclusion Criteria:

1. Sign informed consent and join the study voluntarily;
2. Patients diagnosed with extensive small cell lung cancer;
3. Age ≥18 years old;
4. Have at least one measurable lesion (according to RECIST 1.1);
5. The investigators judged that adebrelimab treatment was acceptable;
6. Contraception: Patients should agree that it must be used during the study period and within 6 months after the study ends Effective contraception;

Exclusion Criteria:

1. Allergic to adebrelimab and its excipients;
2. Patients who have also received other immune drugs or therapies;
3. Patients who are participating in other interventional studies;
4. patients with other malignant tumors;
5. Pregnant or lactating women;
6. The investigator considers that the patient is not suitable to participate in any other conditions of the study.

References

Publications (0)

Data not yet available

No reference posted for this study.